Entrar/Registro  
INICIO ENGLISH
 
Revista de Hematología
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista de Hematología >Año 2014, No. 4


López-Hernández MA, Banda-García L, Alvarado-Ibarra M
Tratamiento de la leucemia mieloide crónica: 20 años de experiencia en una sola institución
Rev Hematol Mex 2014; 15 (4)

Idioma: Inglés
Referencias bibliográficas: 41
Paginas: 164-173
Archivo PDF: 413.10 Kb.


Texto completo




RESUMEN

Antecedentes: el tratamiento de la leucemia mieloide crónica Ph+ ha cambiado rápidamente de la quimioterapia, en el siglo pasado, a la actual administración de inhibidores de la tirosina cinasa. Los resultados han mejorado en términos de supervivencia global.
Objetivo: analizar los resultados obtenidos con diferentes tipos de tratamiento en pacientes con leucemia mieloide crónica Ph+, atendi- dos en el Servicio de Hematología del Centro Médico Nacional 20 de Noviembre, ISSSTE, en la Ciudad de México.
Material y método: estudio observacional, longitudinal, retrospectivo, descriptivo y comparativo de pacientes atendidos de 1990 hasta 2010, con leucemia mieloide crónica Ph+ de novo, mayores de 15 años, de cualquier sexo. Se revisaron los expedientes clínicos. Los tratamientos se agruparon en quimioterapia, busulfán o hidroxiurea, interferón (IFN); trasplante de células progenitoras hematopoyéticas e inhibidores de la tirosina cinasa: imatinib, nilotinib o dasatinib.
Resultados: se incluyeron 206 pacientes que recibieron los siguientes tratamientos: quimioterapia (n = 66), interferón (n = 42), trasplante de células progenitoras hematopoyéticas (n = 35, de ellos, ocho fueron no mieloablativos) e inhibidores de la tirosina cinasa (n = 63). La mayor probabilidad de supervivencia global se alcanzó con inhibidores de la tirosina cinasa y trasplante de células progenitoras hematopoyéticas, 0.92 a 200 meses y 0.52 a 250 meses (p = 0.0001). La progresión a fase acelerada o blástica fue 4 y 2 (p = NS). La mortalidad fue de 9.5 y 48% (p = 0.001). La probabilidad de supervivencia con interferón o quimioterapia fue menor de 100 meses.
Conclusión: los inhibidores de la tirosina cinasa son la mejor opción terapéutica contra la leucemia mieloide crónica Ph+. Sin ser curativos, permiten largas supervivencias con toxicidad comúnmente aceptable. La segunda opción es el trasplante de células progenitoras hematopoyéticas que, aunque no es universalmente aplicable, es curativo, con el inconveniente de causar morbilidad y mortalidad altas. Estos resultados son similares a los reportados en otros centros


Palabras clave: leucemia mieloide crónica, tratamiento, supervivencia.


REFERENCIAS

  1. Rabinowitz I, Larson R. Chronic myeloid leukemia. In: Greer J, Foerster J, Lukens JN, editors. Wintrobe’s Clinical Hematology. 11th ed. Philadelphia: Lippincott Williams & Wilkins Publishers, 2004;2235-2258.

  2. WHO classification of tumours of hematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. 4th ed. 2008.

  3. Pavlovsky C, Kantarjian H, Cortes J. First-line therapy for chronic myeloid leukemia: past, present and future. Am J Hematol 2009;84:287-293.

  4. Silver R, Woolfe S, Kantarjian. An evidence based analysis of the effect of busulfan, hidroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia, developed for the ASH. Blood 1999;94:1517-1536.

  5. Chronic Myeloid Leukemia Trialist’ Collaborative Group. Hydroxyurea versus busulfan for chronic myeloid leukemia: an individual patient data meta-analysis of three randomized trials. Br J Hematol 2000;110:573-576.

  6. Sokal JE, Cox EB, Baccarani M, Tura S, et al. Prognostic discrimination in “good risk” chronic granulocytic leukemia. Blood 1984;63:789-799.

  7. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987;69:1280-1288.

  8. Lindauer M, Fisher T. Interpheron-alfa combined with cytarabine in chronic mielogenous leukemia-clinical benefits. Leuk Lymph 2001;41:523-533.

  9. Angstreich G, Smith B, Jones R. Treatment options forchronic myeloid leukemia: imatinib versus interferon versus allogenic transplant. Curr Opinion Oncology 2004;16:95-99.

  10. Ozer H, George SL, Schiffer CA, Rao K, et al. Prolonged subcutaneous administration of recombinant alpha2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival. Cancer and Leukemia Group B Study 8583. Blood 1993;82:2975-2985.

  11. Baccarani M, Saglio G, Goldman J, Hochhaus A, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809-1820.

  12. Druker BJ, Tamura S, Buchdunger E, Ohno S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.

  13. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002;346:683-693.

  14. O’Brien S, Guilhot F, Druker J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase, chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.

  15. Palandri F, Iacobucci I, Baccarani M. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 2008;26:106-111.

  16. Palandri F, Testoni N, Breccia M, Luatti S, et al. The longterm durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009;94:205-212.

  17. Saglio G, Kim DW, Issaragrisil S, le Coutre P, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.

  18. Kantarjian H, Shah NP, Hochhaus A, Cortes J, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloide leukemia. N Engl J Med 2010;362:2260-2270.

  19. Apperley JF, Cortes JE, Kim DW, Roy L, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure. J Clin Oncol 2009;27:3472-3479.

  20. Shieh MP, Mitsuhashi M, Lilly M. Moving on up: Second-line agents as initial treatment for newly-diagnosed patients with chronic phase CML. Oncology 2011;5:185-199.

  21. Ou J, Vergilio J, Bagg A. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Am J Hematol 2008;83:296-302.

  22. Quintás-Cardama A, Cortes J, Molecular biology of Bcr-Abl1-positive chronic myeloid leukemia. Blood 2009;113:1619-1630.

  23. Kantarjian HM, Talpaz M, O’Brien S, Kurzrock R, et al. Chronic myelogenous leukemia--progress at the MD Anderson Cancer Center over the past two decades and future directions: first Emil J. Freireich Award Lecture 1997;3:2723-2733.

  24. Canellos GP. Neoplastic disease of the blood. 2th ed. New York: Churchil Livingstone INC, 1991.

  25. López Hernández MA, Flores-Chapa JD, Trueba Christy E, Borbolla Escoboza JR, Carrillo Rosales T. Busulfan versus busulfan-interferon as maintenance therapy in chronic myeloid leukemia. Rev Invest Clin 1996;48:281-287.

  26. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Presented in part at the Education Session of the American Society of Hematology, 1998, Miami Beach. Blood 1999;94:1517-1536.

  27. Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012;26:761-767.

  28. Garcia-Manero G, Faderl S, O’Brien S, Cortes J, et al. Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer 2003;98:437-457.

  29. Baccarani M, Saglio G, Goldman J, Hochhaus A, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net 2009.

  30. Vela-Ojeda J, Tripp-Villanueva F, Sanchez-Cortes E, Ayala- Sanchez M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience. Arc Med Res 2000;31:206-209.

  31. Robin M, Guardiola P, Devergie A, Yeshurun M, et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 2005:19:1613-1620.

  32. Tanaka MF, Kantarjian H, Cortes J, Ohanian M, Jabbour E. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother 2012;13:815-828.

  33. Gratwohl A, Brand R, Apperley J, Crawley C, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long term data and current results: an analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-521.

  34. Giralt S, Ballen K, Rizzo D, Bacigalupo A, et al. Intensity conditioning regimen workshopdefining the dose spectrum: Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2009;15:367-369.

  35. Crawley C, Szydlo R, Lalacette M, Bacigalupo A, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969-2976.

  36. Warlick E, Woo Ahn K, Pedersen TL, Artz A, et al. Intensity conditioning is superior to nonmyeloablative conditioning for older chronic mielogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012:119:4083-4090.

  37. Ruiz-Arguelles G, Gomez-Almaguer D, Morales-Toquero A, Gutierrez-Aguirre CH, et al. The early referral for reducedintensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplantation 2005;36:1043-1047.

  38. Shieh MP, Mitsuhashi M, Lilly M. Moving on up: Second-line agents as initial treatment for newly-diagnosed patients with chronic phase CML. Clinical Medicine Insights: Oncology 2011;5:185-199.

  39. Kantarjian H, Giles F, Gattermann N, Bhalla K, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-3546.

  40. Talpaz M, Shah NP, Kantarjian H, Donato N, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541.

  41. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-4442.



>Revistas >Revista de Hematología >Año2014, No. 4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019